News
You can now review and comment on this draft guideline. The consultation closes on Tuesday 08 July 2025 at 5pm. In line with NICE’s commitment to incorporate technology appraisals (TAs) within ...
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...
Obecabtagene autoleucel (obe‑cel) should not be used to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults.
Subscribe to our newsletters, alerts and awareness service. Keep up to date with the latest evidence based information across health and social care.
Notice of Appeal Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] NICE has received 1 appeal, that falls within one or more of the two strictly ...
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee D, which includes the chair, vice ...
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults ...
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results